Effects of systemic inflammation on relapse in early breast cancer

[1]  J. Satagopan,et al.  Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors , 2019, Breast.

[2]  Wei Jiang,et al.  A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation , 2018, Breast Cancer Research and Treatment.

[3]  A. Seif,et al.  The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia , 2017, American journal of hematology.

[4]  E. Simpson,et al.  Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. , 2016, Current opinion in pharmacology.

[5]  B. Walker,et al.  Derivatization of estrogens enhances specificity and sensitivity of analysis of human plasma and serum by liquid chromatography tandem mass spectrometry , 2016, Talanta.

[6]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[7]  Mitch Dowsett,et al.  Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers , 2014, Breast Cancer Research.

[8]  C. Madeddu,et al.  Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer , 2014, Journal of cellular and molecular medicine.

[9]  C. Ulrich,et al.  A Review of the Application of Inflammatory Biomarkers in Epidemiologic Cancer Research , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[10]  A. Moon,et al.  Inflammatory and microenvironmental factors involved in breast cancer progression , 2013, Archives of Pharmacal Research.

[11]  L. Natarajan,et al.  Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[12]  D. McMillan.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[13]  P. Hojman,et al.  The role of intratumoral and systemic IL-6 in breast cancer , 2013, Breast Cancer Research and Treatment.

[14]  M. Dowsett,et al.  Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance , 2013, Clinical Cancer Research.

[15]  M. Wicha,et al.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.

[16]  Tyler J. VanderWeele,et al.  Estimating measures of interaction on an additive scale for preventive exposures , 2011, European Journal of Epidemiology.

[17]  T. Rebbeck,et al.  Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors , 2011, Breast Cancer Research.

[18]  P. Lønning,et al.  Intratumoral Estrogen Disposition in Breast Cancer , 2010, Clinical Cancer Research.

[19]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Ulrich,et al.  Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Gray,et al.  Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. , 2009, Cancer research.

[22]  William D. Figg,et al.  Validation of Analytic Methods for Biomarkers Used in Drug Development , 2008, Clinical Cancer Research.

[23]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Elder,et al.  Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Heike Knüpfer,et al.  Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.

[26]  A. Marino,et al.  Cinacalcet, fetuin-A and interleukin-6. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  D. Hayes,et al.  Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. , 2006, The oncologist.

[28]  J. Bartlett,et al.  Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer , 2006, British Journal of Cancer.

[29]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[30]  S. Humphries,et al.  Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery. , 2004, Biochimica et biophysica acta.

[31]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[32]  S Lemeshow,et al.  Confidence interval estimation of interaction. , 1992, Epidemiology.

[33]  D. Schultz,et al.  Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. , 1990, Seminars in arthritis and rheumatism.

[34]  R. Olshen,et al.  Points of Significance: Classification and regression trees , 2017, Nature Methods.

[35]  A. Ahlbom,et al.  Interaction: A word with two meanings creates confusion , 2005, European Journal of Epidemiology.